Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Completed1
Enrolling by invitation1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

completed133%
enrolling_by_invitation133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitationnot_applicable

Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases

NCT07567664
completednot_applicable

Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy

NCT04453917
unknown

Description and Modeling of Swallowing Disorders After a Stroke

NCT02974530

Clinical Trials (3)

Showing 3 of 3 trials
NCT07567664Not Applicable

Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases

Enrolling By Invitation
NCT04453917Not Applicable

Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy

Completed
NCT02974530

Description and Modeling of Swallowing Disorders After a Stroke

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3